Isofol Medical: Key parameters of study design accepted by FDA

Research Note

2018-01-17

10:58

Isofol Medical reported that the company has had a successful meeting with the FDA concerning the planned phase III trial in colorectal cancer. The FDA has accepted key parameters of the study design and confirmed that they will accept a successful trial outcome as support for market approval of Modufolin.

AN

Arvid Necander

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.